The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema

Ophthalmology

Volumn 118, Issue 4, 2011, Pages 615-625

  Mitchell, Paul ^a   Bandello, Francesco ^b   Schmidt Erfurth, Ursula ^c   Lang, Gabriele E ^d   Massin, Pascale ^e   Schlingemann, Reinier O ^f   Sutter, Florian ^g   Simader, Christian ^c   Burian, Gabriela ^h   Gerstner, Ortrud ^h   Weichselberger, Andreas ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e HÔPITAL LARIBOISIÈRE   (France)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ANGINA PECTORIS; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; ENDOPHTHALMITIS; EPISTAXIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEART INFARCTION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; LASER SURGERY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RETINA; RETREATMENT; SICKNESS IMPACT PROFILE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79953311138     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.01.031     Document Type: Article

References (22)

1. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-70. (Pubitemid 24183163)
2. Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64:16-20.
3. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twentyfive- year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
5. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 1987;94:761-74.
6. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-59.
7. Diabetic Retinopathy Clinical Research Network (DRCR. net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. (Pubitemid 24356306)
9. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
10. Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405.
11. Nguyen QD, Shah SM, Khwaja AA, et al, READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2010;117:2146-51.
12. West SK, Rubin GS, Broman AT, et al, SEE Project Team. How does visual impairment affect performance on tasks of everyday life? The SEE Project. Arch Ophthalmol 2002;120:774-80.
13. Chia EM, Wang JJ, Rochtchina E, et al. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004;45:71-6. (Pubitemid 38055670)
14. Owen CG, Rudnicka AR, Smeeth L, et al. Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? BMC Ophthalmol [serial online] 2006;6:24. Available at: http://www.biomedcentral.com/1471-2415/6/24. Accessed December 20, 2010.
15. Suner IJ, Kokame GT, Yu E, et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 2009;50:3629-35.
16. Ferreira PL, Ferreira LN, Pereira LN. How consistent are health utility values? Qual Life Res 2008;17:1031-42.
17. Clinicaltrials.gov. Genentech. A study of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RISE). ClinicalTrials.gov Identifier NCT00473330. Available at: http://clinicaltrials.gov/ct2/show/NCT00473330. Accessed November 15, 2010.
18. Clinicaltrials.gov. Genentech. A study of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RIDE). ClinicalTrial.gov Identifier NCT00473382. Available at: http://clinicaltrials.gov/ct2/show/NCT00473382. Accessed December 20, 2010.
19. Rosenfeld PJ, Brown DM, Heier JS, et al, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
20. Brown DM, Michels M, Kaiser PK, et al, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration [ANCHOR study 1-year data]. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
21. Clinicaltrials.gov. Novartis. Efficacy and safety of ranibizumab (intravitreal injections) in patients with visual impairment due to diabetic macular edema (REVEAL). ClinicalTrial.gov Identifier NCT00989989. Available at: http://clinicaltrials.gov/ct2/show/NCT00989989. Accessed December 20, 2010.
22. Clinicaltrials.gov. Novartis. Efficacy and safety of ranibizumab in two "treat and extend" treatment algorithms versus ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus (RETAIN). ClinicalTrial.gov IdentifierNCT01171976. Available at: http://clinicaltrials.gov/ct2/show/NCT01171976. Accessed December 20, 2010.